JPRN-UMIN000019093
Recruiting
Phase 2
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14) - Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 sites50 target enrollmentOctober 1, 2015
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- s lymphoma
- Sponsor
- Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Cases where impaired liver, kidney and cardiac functions compromise experimental treatment (2\) Patients who have been treated with anticancer drugs or radiation therapy (3\) Presence of CNS degenerative lesion (4\) Associated intracranial hemorrhage which hinders execution of treatment process (5\) Associated infection which is difficult to control (6\) Pregnant or possibility of pregnancy (7\) Women who are breastfeeding (8\) Past history of malignant neoplasm or multiple primary neoplasms (9\) History of congenital or acquired immune deficiency syndrome (10\) Any other reasons that the attending physician has deemed unsuitable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)JPRN-jRCTs041180174Koga Yuhki50
Recruiting
Not Applicable
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 TherapyMetastatic MelanomaNCT03888950Centre Hospitalier Universitaire de Nice20
Recruiting
Not Applicable
Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)Metastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000052831Chang Gung Memorial Hospital30
Completed
Phase 2
A clinical trial to see whether outcomes in Hodgkins Lymphoma can be improved by using increased intensity therapy in interim PET scan positive patientsHealth Condition 1: null- Advanced Hodgkins Lymphoma (Stage IIb, III, IV)Health Condition 2: C819- Hodgkin lymphoma, unspecifiedHealth Condition 3: C819- Hodgkin lymphoma, unspecifiedCTRI/2012/06/002741Cancer Institute50
Active, not recruiting
Phase 1
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyAdvanced stage Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10020206Term: Hodgkin's diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10020243Term: Hodgkin's disease NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000498-35-PLEuropean Organisation for Research and Treatment of Cancer (EORTC)150